Metraipolis › archive › dc_4b036942eaa4
Checkpoint inhibitor effectiveness after corticosteroids and second-line immunosuppressants for immune-related adverse events in non-small-cell lung cancer — Europe PMC PMID:41564819
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41564819
- DOI
- 10.1016/j.esmoop.2025.106052
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T16:33:06.525Z
- SHA-256 of the archived text
43f45272d2ef26628b696203ed769e188ca25e556a9b62eccc05f61cc4f83114- Stable URL of this page
https://metraipolis.com/documento/dc_4b036942eaa4
How to cite
Checkpoint inhibitor effectiveness after corticosteroids and second-line immunosuppressants for immune-related adverse events in non-small-cell lung cancer — Europe PMC PMID:41564819 — Europe PMC (en), https://europepmc.org/article/MED/41564819 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4b036942eaa4 (Metraipolis archive dc_4b036942eaa4, sha256 43f45272d2ef26628b696203ed769e188ca25e556a9b62eccc05f61cc4f83114)
BibTeX
@misc{dc4b036942eaa4,
title = {Checkpoint inhibitor effectiveness after corticosteroids and second-line immunosuppressants for immune-related adverse events in non-small-cell lung cancer — Europe PMC PMID:41564819},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41564819},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4b036942eaa4; sha256 43f45272d2ef26628b696203ed769e188ca25e556a9b62eccc05f61cc4f83114},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41564819. Agents can read the archived copy with the MCP tool read_document.